glucagon
Enable an agent to recognise glucagon, assess its molecular and functional state, and determine whether a particular material is suitable for a specified biological, analytical or pharmaceutical use.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an agent to recognise glucagon, assess its molecular and functional state, and determine whether a particular material is suitable for a specified biological, analytical or pharmaceutical use.
Glucagon is a 29-amino-acid peptide hormone produced principally by pancreatic alpha cells through processing of proglucagon, which raises blood glucose chiefly by stimulating hepatic glycogen breakdown and gluconeogenesis.
It can be Match a substance record or sample to a defined glucagon sequence and molecular form.; Compare glucagon preparations on a consistent peptide-content and purity basis.; Assess whether chemical identity, aggregation and potency evidence support a proposed experiment.; Select handling and storage conditions supported for the specific preparation.; Trace unexpected assay behaviour to cross-reactivity, degradation, aggregation or composition differences.; Accept, quarantine or reject material against documented use-specific criteria..
Distinguishing features
Confirm the mature glucagon sequence and termini; identifying a proglucagon-derived peptide alone does not establish glucagon identity.
Distinguish glucagon from GLP-1 and GLP-2 by sequence and processing identity, despite their shared precursor relationship.
Distinguish native-sequence glucagon from modified analogues by substitutions, conjugation and terminal modifications; receptor activity alone is insufficient.
Distinguish glucagon content from the total mass of a salt-containing, hydrated or formulated preparation.
Distinguish intact, functionally active glucagon from fragments or aggregates that may still produce a glucagon-related analytical signal.
Scope
+ Mature glucagon sequence, molecular form and substance identifiers
+ Relationship to proglucagon, biological source and production route
+ Preparation-specific content, purity, impurities and aggregation
+ Glucagon-receptor activity and the conditions under which it is measured
+ Storage, handling, stability and material-grade restrictions
- Whole-body glucose regulation and pancreatic physiology
- Proglucagon and other precursor-derived peptides as independent substances
- Glucagon analogues and multi-receptor agonists as independent substances
- Finished medicines, delivery devices and their product authorisations
- Patient diagnosis, prescribing, dosing and emergency treatment protocols
- Manufacturing facilities and production processes as operational systems
Characteristics
- Mature peptide identity
- Amino-acid sequence, residue count, termini and reference accession Establishes whether the substance is glucagon rather than a precursor fragment, related peptide or analogue.
- Molecular form
- Unmodified or modified peptide; counterion, hydration and solvation state Controls identity boundaries and the interpretation of weighed material.
- Substance identifiers
- Verified CAS, PubChem, EC or other identifiers with the exact form each identifies Supports record matching without treating identifiers for different forms or products as interchangeable.
- Biological and production origin
- Species and precursor reference; endogenous isolation, recombinant production or chemical synthesis Connects the material to its sequence reference and likely impurity profile.
- Glucagon content
- mg per container, mg/mL or mol/L, with assay and mass basis Separates actual peptide quantity from gross preparation mass.
- Purity and impurity profile
- Method-specific purity percentage; identified and unidentified impurity levels Shows whether fragments, related peptides or process residues constrain the proposed use.
- Physical and aggregation state
- Dry or dissolved; soluble monomer, oligomer, fibril or precipitate, with method and conditions Helps distinguish an apparently intact preparation from material with altered availability or performance.
- Receptor-mediated potency
- Assay-specific concentration-response parameters or relative potency against a named reference Tests functional activity independently of chemical identity or immunoreactivity.
- Stability conditions
- Temperature in °C, pH, concentration, elapsed time and handling history Makes stability assessments specific to the actual preparation and its exposure history.
- Material qualification
- Research material, analytical reference or pharmaceutical substance; documented acceptance status Determines which uses the available quality evidence supports.
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 19 findings · 29 questions.
Mature peptide identity Defines the glucagon molecule represented by the entry and separates it from neighbouring peptide identities.
A glucagon label or positive assay signal does not by itself establish the mature molecular species.
Sequence and form
Establishes the reference sequence and the chemical form of the represented material.
Sequence identity
Record sequence, termini and modifications against an identified reference before accepting a material as glucagon.
- Which mature glucagon sequence, species reference and terminal structures define this material? definition
- What analytical evidence confirms that sequence and excludes substitutions, truncations or conjugation? measurement
Identifiers and neighbours
Maps identifiers to exact substance forms while keeping precursors and analogues distinct.
Identity boundaries
Treat identifiers as form-specific evidence and explicitly distinguish glucagon from proglucagon, related peptides and finished products.
- Which verified identifiers refer to this peptide form rather than a salt, formulation or branded medicine? provenance
- Does the represented entity remain glucagon, or does its sequence or modification require a separate analogue model? boundary
Origin and preparation composition Connects glucagon to its precursor or production source and establishes what a preparation contains.
Identical peptide names can conceal different origins, content bases and impurity profiles.
Precursor and production origin
Records biological processing context or the route used to obtain the peptide.
Origin traceability
Link the mature peptide to a documented biological source or production route without treating that route as its identity.
- For endogenous material, which species, tissue and precursor-processing evidence establish mature glucagon? provenance
- For manufactured material, what production route and batch documentation support the declared peptide identity? provenance
Content and related substances
Separates glucagon quantity from counterions, water, additives and peptide impurities.
Composition basis
Report peptide content and impurity measurements with their analytical methods and calculation bases.
- Is the stated amount based on glucagon peptide, gross powder mass or a formulated preparation, and how were water and counterions accounted for? measurement
- Which related peptides, degradation products and process residues were measured, and which remain unresolved? measurement
Physical state and stability Tracks whether glucagon remains dissolved, chemically intact and suitably dispersed under actual handling conditions.
A preparation's usable state cannot be inferred from its initial identity or nominal concentration.
Solution and aggregation
Characterises dissolution, aggregation and precipitation in a specified medium.
Available peptide state
Assess soluble peptide and aggregation using methods capable of detecting changes beyond visible precipitation.
- At what pH, concentration, temperature and solvent composition was glucagon dissolved and characterised? measurement
- What evidence distinguishes soluble monomer from oligomers, fibrils or precipitated material in this preparation? measurement
Handling history and integrity
Relates chemical integrity and recovery to storage, reconstitution and subsequent exposure.
Preparation-specific stability
Apply stability evidence only to the molecular form, medium, container and handling conditions it covers.
- What storage, reconstitution, agitation, freeze-thaw and container-contact history has this material experienced? provenance
- Which measured changes in intact peptide, recovery or aggregation determine whether it can still be used? action
Biological activity and detection Distinguishes receptor-mediated function from analytical detection of glucagon-related material.
Chemical content, immunoreactivity and biological potency answer different questions about a glucagon sample.
Receptor-mediated function
Measures glucagon activity in a defined receptor and assay context.
Functional potency
Attach potency claims to a receptor system, response endpoint and reference preparation.
- Which receptor species, assay system and response endpoint were used to measure glucagon activity? measurement
- How does the concentration-response relationship compare with a qualified glucagon reference under the same conditions? measurement
Analytical specificity
Establishes what a reported glucagon signal actually measures.
Signal interpretation
Interpret glucagon measurements in light of assay selectivity, sample matrix and preanalytical handling.
- Can this method distinguish mature glucagon from precursor-derived peptides, fragments and modified forms? boundary
- What matrix effects, sample handling losses or cross-reactivity could change the reported glucagon concentration? measurement
Material qualification and use Connects the evidence about a glucagon preparation to permissible material-level actions.
Recognising glucagon does not establish that a particular batch meets the requirements of its intended use.
Grade and acceptance
Defines use-specific qualification without inheriting the status of a finished medicine.
Fitness for intended use
Assess material against documented requirements for reference, research or pharmaceutical-substance use.
- What intended use and material grade are claimed, and which certificates or specifications support them? provenance
- Which identity, content, impurity, potency and relevant microbiological criteria must pass before this batch is accepted? action
Handling and product boundary
Records applicable substance handling evidence and separates material decisions from clinical product decisions.
Supported actions
Ground laboratory handling in the specific preparation's documentation and route clinical decisions to the relevant product and care models.
- Which current safety documentation and jurisdiction-specific classifications apply to this exact glucagon preparation? provenance
- Which proposed actions are supported by material qualification, and which require a finished-product authorisation or clinical protocol? boundary
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This account uses recalled knowledge, without consulted sources; confirm identifiers and current compendial requirements before publication.
- Production categories do not necessarily differ in peptide sequence; purity, impurities, potency and formulation distinguish particular preparations.
- Product-specific labeling should establish contraindications and storage requirements; no universal GHS classification, melting point or boiling point is asserted here.
- Which of these check these first hold for the sense of glucagon this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Endogenous glucagon
- Recombinant human glucagon
- Chemically synthesized glucagon
- Which of these kinds and varieties hold for the sense of glucagon this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- CAS Registry Number - 16941-32-5 - Identifies glucagon; formulations, salts and peptide analogues require separate identity checks.
- International Nonproprietary Names (WHO) - glucagon - Names the medicinal active substance rather than a particular finished product.
- Which of these identifiers and schemes hold for the sense of glucagon this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- United States Pharmacopeia-National Formulary (USP-NF), issued by the United States Pharmacopeial Convention, includes compendial requirements for glucagon.
- US Food and Drug Administration approval and prescribing information govern individual glucagon medicinal products in the United States.
- Which of these standards and regulation hold for the sense of glucagon this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Endogenous regulation of blood glucose during fasting and hypoglycemia.
- Medicinal treatment of severe hypoglycemia.
- Temporary inhibition of gastrointestinal motility during selected diagnostic procedures.
- Research on pancreatic endocrine function, hepatic metabolism and glucagon-receptor signaling.
- Which of these real-world use hold for the sense of glucagon this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Length of the mature human peptide - 29 - amino-acid residues
- Average molecular mass of unmodified human glucagon - Approximately 3482.8 - Da
- Which of these typical measurements hold for the sense of glucagon this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Medicinal administration can cause nausea and vomiting.
- The glucose-raising response can be reduced when hepatic glycogen stores are depleted.
- Glucagon can aggregate or form fibrils in solution; stability depends on formulation, temperature, pH and storage time.
- Hypersensitivity reactions can occur with medicinal products.
- Medicinal glucagon has contraindications involving pheochromocytoma and insulinoma because of potentially dangerous physiological responses.
- Which of these failure modes and hazards hold for the sense of glucagon this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Approved indications, routes of administration, formulations and availability differ between jurisdictions.
- Which of these regional variation hold for the sense of glucagon this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Proglucagon - Proglucagon is the larger precursor polypeptide; glucagon is one of its tissue-dependent processing products.
- Glucagon-like peptide-1 - GLP-1 is a distinct proglucagon-derived peptide acting through a different receptor and promoting glucose-dependent insulin secretion.
- Insulin - Insulin is a distinct pancreatic beta-cell hormone that generally lowers blood glucose, whereas glucagon promotes hepatic glucose output.
- Glucagon receptor - The receptor is the membrane signaling protein activated by glucagon; glucagon is its peptide ligand.
- Dasiglucagon - Dasiglucagon is a sequence-modified glucagon analogue, rather than the native human peptide.
- Glucagon medicinal product - A finished medicine contains glucagon together with a specified formulation and delivery system; the registered substance is the peptide itself.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of glucagon this model covers, and on what evidence? provenance
What the second pass must settle
- Does this registry entry cover glucagon across species or specifically the human mature sequence, and which reference establishes that boundary?
- Which authoritative identifiers distinguish the peptide from salt forms, hydrated materials and medicinal preparations?
- Which stability and aggregation limits are supported for the relevant concentrations, solvents, containers and handling conditions?
- Which analytical methods adequately separate mature glucagon from related precursor products in the intended sample matrices?
- Which current material specifications, hazard classifications and jurisdiction-specific requirements apply to each intended grade and use?